Author

J. Koo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:Drosophila· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. I. Marcus· 2 shared C.-S. Seong· 2 shared H. Claussen· 2 shared H. Fu· 2 shared H. R. Johnston· 2 shared M. Gilbert-Ross· 2 shared S. S. Ramalingam· 2 shared W. Zhou· 2 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. I. Marcus

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer

J. Koo, C.-S. Seong, R. E. Parker, B. Dwivedi, R. A. Arthur, A. R. Dinasarapu, H. R. Johnston, H. Claussen, C. Tucker-Burden, S. S. Ramalingam, H. Fu, W. Zhou, A. I. Marcus, M. Gilbert-Ross

This study identifies the ALK2/BMP6 iron homeostasis pathway as a therapeutic target in LKB1-mutant lung cancer using live-cell imaging and transcriptome analysis.

bioRxiv · Jun 14, 2023 · PreprintCancer Biology

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.

C.-S. Seong, C. Huang, A. C. Boese, Y. Hou, J. Koo, J. K. Mouw, M. Rupji, G. Joseph, H. R. Johnston, H. Claussen, J. M. Switchenko, M. Behera, M. Churchman, J. M. Kolesar, S. M. Arnold, , M. Gilbert-Ross

The paper shows that loss of HD-PTP, a tumor suppressor, promotes RAS-driven oncogenesis and is associated with adenosquamous lung cancer, suggesting it as a therapeutic target.

bioRxiv · Jan 26, 2023 · PreprintCancer Biology